Therapy
Biotechnology
Health

Exelixis

$20.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.59 (2.98%) Today
-$0.34 (-1.69%) After Hours

Why Robinhood?

You can buy or sell Exelixis and other stocks, options, ETFs, and crypto commission-free!

About

Exelixis, Inc. Common Stock, also called Exelixis, is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. Read More It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.

Employees
484
Headquarters
Parkway Alameda, California
Founded
1994
Market Cap
6.14B
Price-Earnings Ratio
9.79
Dividend Yield
0.00
Average Volume
3.90M
High Today
$20.41
Low Today
$19.80
Open Price
$19.83
Volume
922.31K
52 Week High
$25.31
52 Week Low
$13.42

Collections

Therapy
Biotechnology
Health
Cancer Prevention
Pharmaceutical
Biopharmaceutical
Medical
Technology

News

Financial PostMay 24

New Investigational Clinical Data for Ipsen's Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting

PARIS — Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: Ne...

97
Seeking AlphaMay 21

Exelixis: Good Time To Buy

Exelixis, Inc. (EXEL), a mid-sized pharmaceutical, is a strong buy, forecast to double in the next five years, with potential to do much better than that. Analysis EXEL is intriguing on several counts. First, it came through a simple screen for (A) FDA-approved drugs, (B) positive cash flow from operating activities, (C) rated as a consensus “buy” among analysts cited by Yahoo, (D) often beats Street estimates for quarterly earnings, and finally, (E) EXEL is expected to maintain a near-term annual growth ...

421
Yahoo FinanceMay 16

Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- ̶ ICON-2 program targets Tissue Factor (TF) with potential broad impact in oncology ̶ ̶ Exelixis will make upfront payment and contribute research funding for option to in-license at Investigational New Drug (IND) filing ̶ Scroll to continue with content Ad Exelixis, Inc. (EXEL) today announced that it has entered into an exclusive option and license agreement with Iconic Therapeutics, Inc. (Iconic), a private biopharmaceutical company foc...

4

Earnings

$0.08
$0.19
$0.30
$0.41
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.